The First Prescription Digital Therapeutic Using Virtual Reality Exposure Therapy to Treat Post Traumatic Stress Disorder (PTSD)

reCALL™ for PTSD

Pear Therapeutics has developed reCALL™, a prescription digital therapeutic, to be used in conjunction with pharmaceuticals for reducing the psychological effects of trauma and treating PTSD

Prescription Digital Therapeutic Using Virtual Reality Exposure Therapy + Drug Combination


  • 1 in 3 U.S. soldiers will suffer from PTSD after serving in Iraq or Afghanistan and 2 in 3 soldiers serving multiple tours will experience PTSD1
  • 30 percent of soldiers develop mental health problems within 3 to 4 months of being home1
  • reCALL™ is a prescription digital therapeutic that uses virtual reality-based simulation in which a patient confronts traumatic memories through a retelling of the experience.

patient-facing image6

  • A prescription digital therapeutic that uses Virtual reality exposure therapy (VRET) presents a solution to addressing Military Service Members’ mental health by:
    • Providing accessible treatment anytime anywhere
    • Providing immersive environments to maximize therapeutic benefit
    • Eliminating long waits for clinician availability
    • Allowing standardization of care across a range of treatment settings
1. Rand Corporation. Center for Military Health Policy Research. 2008.

reCALL™ as a Prescription Digital Therapeutic for Treating PTSD and Combat-Related Depression

VRET is a clinically validated treatment that can decrease anxiety and depression, and lower symptom severity of PTSD

  • Over a 5-week period, participants were treated twice weekly with 45 minutes of VRET as part of treatment sessions lasting between 90 and 120 minutes each.
  • At the conclusion of treatment:
    • Average PCL-M scores decreased from pre-treatment levels of 54.4 to 35.6 post-treatment (p<0.001)
    • Average PHQ-9 scores decreased from pre-treatment levels of 13.3 to 7.1 post-treatment (p=0.002)
    • Average BAI scores decreased from pre-treatment levels of 18.6 to 11.9 post-treatment(p=0.003)

Graph 1 PCLM

Graph 2 PHQ9

Graph 3 BAI


Rizzo et al.  Military Medicine.  2012.

Combination therapy involving VRET plus a cognitive enhancer demonstrates improved efficacy

  • In a pilot randomized, double-blind, placebo-controlled trial, VRET plus 100mg of a cognitive enhancer or placebo was administered to 25 patients with chronic PTSD
  • At the conclusion of treatment:
    • Patients receiving combination therapy demonstrated marked improvement in the Clinician Administered PTSD Scale (CAPS; p=0.063 post treatment and p=0.004 at 6-month follow-up) vs patients receiving VRET alone
    • Combination therapy produced a similarly significant impact on the State-Trait Anger Expression Inventory-2 (STAX-2; p=0.009)


Difede et al.  Neuropsychopharmacology.  2014.

For more information, please contact us

Contact Us

reCALL™ is not yet available in the United States